Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comDescription:
The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.
Sponsor:
Central Hospital, Nancy, France
Phase:
N/A
Contacts:
Boursier Caroline, MDc.boursier@chru-nancy.fr
+33383154276
Véronique ROCH, MSCv.roch@chru-nancy.fr
+33383154276
Government Study Link:
NCT06614205 - Click here to see study onClinicalTrials.gov
Help us improve your experience